Efficacy of etoposide for an aged patient with primary cutaneous CD30+T-cell lymphoproliferative disorder

佳直, 渋谷; 智佳子, 荒川; 陽子, 水谷; 真理子, 清島

doi:10.5227/skincancer.22.162

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low‐dose etoposide has been used for the treatment of elderly patients with various types of lymphoma. In Japan, there were some reports of aged patients with PCALCL treated with low‐dose‐oral etoposide, 8–10 although there were only a few reports of PCALCL patients treated with etoposide monotherapy in the English literature (Table 1).…”

Section: Reportmentioning

confidence: 99%

Primary cutaneous CD30+ anaplastic large-cell lymphoma with generalized skin involvement and involvement of one peripheral lymph node, successfully treated with low-dose oral etoposide

Yamane¹,

Kato²,

Nishimura³

et al. 2009

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Primary cutaneous CD30+ anaplastic large-cell lymphoma (PCALCL) in adults is rare, and the prognosis is generally excellent. Multifocal PCALCL tends to relapse after multiagent chemotherapy and is generally considered more prone to progress to extracutaneous involvement than is the localized disease. We report a 43-year-old woman with PCALCL who had generalized skin involvement accompanied by involvement of one peripheral draining lymph-node region. Although the disease relapsed after multiagent chemotherapy regimens, the disease was successfully treated with low-dose etoposide. We reviewed the previously reported cases of PCALCL treated with low-dose etoposide. We suggest that oral etoposide might be a useful effective treatment for treatment of relapsed multifocal PCALCL.

show abstract

Section: Reportmentioning

confidence: 99%